Northwest & Ethical Investments L.P. Has $3.91 Million Position in Zoetis Inc. $ZTS

Key Points

• Northwest & Ethical Investments L.P. has reduced its stake in Zoetis Inc. by 20.8%, now holding 23,739 shares valued at approximately $3.91 million.
• Several other investors have also adjusted their positions, with notable increases including 614.6% by Bfsg LLC and 141.4% by Sound Income Strategies LLC.
• Zoetis recently reported a higher-than-expected EPS of $1.76 for the quarter, exceeding analysts' estimates, and announced a quarterly dividend of $0.50 per share.

Northwest & Ethical Investments L.P. reduced its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 20.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 23,739 shares of the company's stock after selling 6,251 shares during the quarter. Northwest & Ethical Investments L.P.'s holdings in Zoetis were worth $3,908,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Navigoe LLC bought a new position in Zoetis during the fourth quarter valued at about $30,000. Cornerstone Planning Group LLC grew its holdings in shares of Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after purchasing an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after purchasing an additional 120 shares during the period. Sound Income Strategies LLC raised its stake in shares of Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after purchasing an additional 164 shares in the last quarter. Finally, Bfsg LLC raised its stake in shares of Zoetis by 614.6% in the first quarter. Bfsg LLC now owns 293 shares of the company's stock valued at $48,000 after purchasing an additional 252 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of NYSE:ZTS traded down $1.2650 during trading on Thursday, reaching $155.4950. The stock had a trading volume of 2,411,616 shares, compared to its average volume of 3,106,003. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The business's 50-day moving average price is $154.27 and its 200 day moving average price is $158.86. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The stock has a market capitalization of $68.91 billion, a PE ratio of 26.76, a P/E/G ratio of 2.50 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same quarter in the previous year, the company posted $1.56 earnings per share. Zoetis's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ZTS. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and cut their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. UBS Group cut their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Piper Sandler raised their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Finally, Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $202.43.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.18% of the stock is currently owned by corporate insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.